- Home
- BRBR vs BLTE Comparison
BRBR vs BLTE Comparison
Compare BRBR & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRBR | BLTE |
|---|---|---|
| Founded | 2019 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.1B |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BRBR | BLTE |
|---|---|---|
| Price | $17.67 | $174.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 8 |
| Target Price | $43.56 | ★ $181.14 |
| AVG Volume (30 Days) | ★ 2.9M | 152.6K |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $2,316,600,000.00 | N/A |
| Revenue This Year | $6.36 | N/A |
| Revenue Next Year | $6.05 | $218.41 |
| P/E Ratio | $47.69 | ★ N/A |
| Revenue Growth | ★ 16.05 | N/A |
| 52 Week Low | $16.05 | $49.00 |
| 52 Week High | $79.57 | $200.00 |
Technical Indicators
Market Signals| Indicator | BRBR | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 38.81 | 47.46 |
| Support Level | $17.10 | $167.80 |
| Resistance Level | $19.35 | $174.78 |
| Average True Range (ATR) | 0.93 | 8.39 |
| MACD | 0.19 | -1.79 |
| Stochastic Oscillator | 46.21 | 21.02 |
Price Performance
Historical ComparisonAbout BRBR BellRing Brands Inc.
BellRing Brands Inc is a United States-based company engaged in providing nutrition-related products. Its brands, Premier Protein, Dymatize, and PowerBar provides various products including ready-to-drink protein shakes, powders and nutrition bars. The company's products are distributed through a diverse network of channel including club, food, drug and mass, eCommerce, convenience and specialty.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.